Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study

Abstract

The tirapazamine regimen was well tolerated with a compliance rate of 82%. The toxicity of RT with concurrent tirapazamine was acceptable in treating advanced head and neck carcinomas. The disease control trend was encouraging. Further clinical studies are warranted.